ClinicalTrials.gg
RecruitingNCT06672081CATCH-PE IIUpdated Mar 4, 2026

Early Catheter-directed Treatment of High Risk Pulmonary Embolism

An interventional study of Early Catheter-Interventional Treatment and Conventional care in Pulmonary Embolism Acute Massive, sponsored by Leipzig Heart Science gGmbH. Recruiting at 18 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Leipzig Heart Science gGmbH · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Pulmonary Embolism with a site in Germany — 6 open to participants now, 8 under way, 2 of them phase 3. Pulmonary Embolism · Germany.

Planned enrollment
22nd of 33
210 · median 544
Started
2024
with 3 others
No phase
7 of 55
2 open now
Registered
54th of 55
by date

Among the 55 studies in Pulmonary Embolism with a site in Germany, this one is the 22nd largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 with no phase, and was the 54th registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

6 of the 55 studies in Pulmonary Embolism with a site in Germany are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Pulmonary Embolism with a site in Germany, or all of them as a file.
02

Study summary

Prospective, multicenter, open label, randomized controlled clinical trial to compare the effects of an early catheter-directed treatment plus conventional care with conventional care in patients with high-risk pulmonary embolism

03

Conditions studied

  • Pulmonary Embolism Acute Massive

Browse trials for

Keywords

  • pulmonary embolism
  • early catheter-directed treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pulmonary embolism as confirmed by CT angiogram with high mortality risk as defined by ESC guidelines:

    a) One of the following: i. Cardiac arrest or ii. obstructive shock (systolic BP \<90 mmHg or vasopressors required to achieve a BP ≥90 mmHg despite an adequate filling status), in combination with end-organ hypoperfusion (cold, clammy skin, oliguria or serum lactate ≥2 mmol/L) and b) Signs of right-ventricular dysfunction on transthoracic echocardiogram or CT scan

  2. Age ≥18 years

Exclusion criteria

Exclusion Criteria:

  1. for catheter-based treatment
  2. Contraindications to systemic fibrinolytic treatment or anticoagulation*

    1. Active, potentially life-threatening bleeding
    2. Surgery within 24h before screening
    3. Cranial or spinal surgery within 14d before screening
    4. Stroke within 14d before screening
    5. Intracranial tumor
    6. Any condition not listed here but estimated as as judged by the treating investigator
  3. Pregnancy

    • Patients with contraindications to systemic fibrinolysis or anticoagulation can be enrolled in a third study arm (registry) and undergo catheter-directed therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Active comparator
    conventional care

    Patients in the conventional care group will receive guideline directed therapy including reperfusion treatment. If no clinically relevant hemodynamic improvement occurs, catheter-interventional treatment may be used as stated in the current ESC-guidelines

    Drug: Conventional care

  • Experimental
    Early Catheter-Interventional Treatment + conventional care

    Patients in this group will undergo a catheter-interventional treatment within 60 min. after randomization. Fibrinolytic treatment will be prepared parallel to interventional treatment preparations to avoid any delay in its administration, if clinically necessary. Catheter-interventional treatment may include any certified devices for the treatment of PE including aspiration thrombectomy, local fibrinolytic therapy, local ultrasound treatment as assistance to local fibrinolysis or any combination of these. Transfemoral venous access routes will be used for any catheter-directed treatment using sheath-sizes as recommended in the IFUs by the respective manufacturers. Sheaths will be withdrawn immediately after catheter-based thrombectomy or after completion of catheter-directed local fibrinolysis, typically 5 to 10 hours after initiation. The choice of the catheter types and sizes will be left to the treating interventionalists' discretion.

    Procedure: Early Catheter-Interventional Treatment · Drug: Conventional care

Interventions

  • ProcedureEarly Catheter-Interventional Treatment

    Patients will undergo a catheter-interventional treatment within 60 min. after randomization. Fibrinolytic treatment will be prepared parallel to interventional treatment preparations to avoid any delay in its administration if clinically necessary. Catheter-interventional treatment may include any certified devices for the treatment of PE including aspiration thrombectomy, local fibrinolytic therapy, local ultrasound treatment as assistance to local fibrinolysis or any combination of these.Transfemoral venous access routes will be used for any catheter-directed treatment using sheath-sizes as recommended in the IFUs by the respective manufacturers. Sheaths will be withdrawn immediately after catheter-based thrombectomy or after completion of catheter-directed local fibrinolysis, typically 5 to 10 hours after initiation.

  • DrugConventional care

    reperfusion treatment

06

What researchers measure

Primary outcomes

  1. Composite endpoint of mortality (all-cause) and recurrent cardiac arrest or persistent / recurrent shock

    1. mortality (all-cause) up to 7 days after randomization and 2. either one of the following 1. recurrent cardiac arrest or 2. persistent / recurrent shock (systolic BP \<90 mmHg or vasopressors or ECMO required to achieve a systolic BP ≥90 mmHg, in combination with end-organ hypoperfusion (cold, clammy skin, oliguria or serum lactate ≥2 mmol/L) 24 hours after randomization

    Time frame: 7 days

Secondary outcomes

  1. All-cause mortality

    All-cause mortality at day 7 after randomization

    Time frame: 7 days

  2. PE-related mortality

    PE-related mortality at day 7 after randomization

    Time frame: 7 days

  3. Mortality (all-cause)

    Mortality (all-cause) at day 30 after randomization

    Time frame: 30 days

  4. Bail out therapy

    Bail out therapy at day 7 after randomization

    Time frame: 7 days

  5. GUSTO moderate or severe bleeding

    GUSTO moderate or severe bleeding up to 7 days after randomization

    Time frame: 7 days

  6. VA-ECMO use

    VA-ECMO use between randomization and day 7 after randomization

    Time frame: 7 days

  7. Change in echocardiographic parameters

    Change in echocardiographic parameters (RV/LV ratio, RV-strain, TAPSE) 24h after randomization

    Time frame: 24 hours

  8. Days of ICU stay

    Days of ICU stay

    Time frame: 30 days

  9. Time to hemodynamic stabilization

    Time to hemodynamic stabilization

    Time frame: 30 days

07

Study locations

18 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jun 2027, 30 months after the start.

Of 125 non-industry interventional studies with no phase under Pulmonary Embolism, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 30 months is above that.

Counting every sponsor, half of 150 studies reached it within 25 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 4, 2024
StartActual
Dec 27, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06672081
Lead sponsor
Leipzig Heart Science gGmbH
Collaborators
Heart Center Leipzig at University of Leipzig, Helios Health Institute GmbH
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Dec 27, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Karl Fengler, MD, Assoc. Prof.
Contact
karl.fengler@medizin.uni-leipzig.de
+49 341 865-1426
Holger Thiele, MD, Prof. Dr.
Contact
holger.thiele@medizin.uni-leipzig.de
Karl Fengler, MD, Assoc. Prof.
study chair · Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology
Holger Thiele, MD. Prof.
study chair · Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion